Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Viracta Therapeutics (Nasdaq: VIRX), a clinical-stage precision oncology company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 11, 2024, at 8:30 a.m. EDT in New York City. Mark Rothera, President and CEO of Viracta, will be presenting at the conference.
Viracta focuses on developing treatments for virus-associated cancers that affect patients worldwide. Investors and interested parties can access a live webcast of the presentation through the company's website under the 'Events and Presentations' section. The webcast will remain archived for 90 days following the event, allowing for later viewing.
Viracta Therapeutics (Nasdaq: VIRX), un'azienda di oncologia di precisione in fase clinica, ha annunciato la sua partecipazione alla 26a Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. L'evento è programmato per l'11 settembre 2024, alle 8:30 a.m. EDT nella città di New York. Mark Rothera, Presidente e CEO di Viracta, presenterà alla conferenza.
Viracta si concentra sullo sviluppo di trattamenti per cancro associato a virus che colpiscono pazienti in tutto il mondo. Investitori e parti interessate possono accedere a un webcast dal vivo della presentazione attraverso il sito web dell'azienda nella sezione 'Eventi e Presentazioni'. Il webcast rimarrà archiviato per 90 giorni dopo l'evento, consentendo la visione successiva.
Viracta Therapeutics (Nasdaq: VIRX), una empresa de oncología de precisión en etapa clínica, anunció su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright. El evento está programado para el 11 de septiembre de 2024, a las 8:30 a.m. EDT en la ciudad de Nueva York. Mark Rothera, Presidente y CEO de Viracta, estará presentando en la conferencia.
Viracta se centra en desarrollar tratamientos para cánceres asociados a virus que afectan a pacientes en todo el mundo. Los inversores y partes interesadas pueden acceder a un webcast en vivo de la presentación a través del sitio web de la empresa en la sección de 'Eventos y Presentaciones'. El webcast permanecerá archivado durante 90 días después del evento, permitiendo la visualización posterior.
Viracta Therapeutics (Nasdaq: VIRX)는 임상 단계의 정밀 종양학 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 11일, 오전 8:30 EDT에 뉴욕에서 개최될 예정입니다. Mark Rothera는 Viracta의 대표이자 CEO로서 콘퍼런스에서 발표할 예정입니다.
Viracta는 전 세계 환자에게 영향을 미치는 바이러스 관련 암 치료법 개발에 집중하고 있습니다. 투자자와 관심 있는 분들은 회사 웹사이트의 '이벤트 및 발표' 섹션을 통해 발표의 실시간 웹캐스트에 접속할 수 있습니다. 웹캐스트는 행사가 끝난 후 90일 동안 아카이브되어 후에 시청할 수 있습니다.
Viracta Therapeutics (Nasdaq: VIRX), une entreprise d'oncologie de précision en phase clinique, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. L'événement est prévu pour le 11 septembre 2024, à 8h30 EDT à New York. Mark Rothera, Président et CEO de Viracta, présentera à la conférence.
Viracta se concentre sur le développement de traitements pour les cancers associés aux virus qui touchent des patients dans le monde entier. Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via le site web de l'entreprise dans la section 'Événements et Présentations'. Le webinaire restera archivé pendant 90 jours après l'événement, permettant une consultation ultérieure.
Viracta Therapeutics (Nasdaq: VIRX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, hat seine Teilnahme an der 26. jährlichen globalen Investmentkonferenz von H.C. Wainwright angekündigt. Die Veranstaltung findet am 11. September 2024 um 8:30 Uhr EDT in New York City statt. Mark Rothera, Präsident und CEO von Viracta, wird auf der Konferenz präsentieren.
Viracta konzentriert sich auf die Entwicklung von Behandlungen für virusassoziierte Krebserkrankungen, die Patienten weltweit betreffen. Investoren und Interessierte können über die Unternehmenswebsite im Abschnitt 'Veranstaltungen und Präsentationen' auf einen Live-Webcast der Präsentation zugreifen. Der Webcast bleibt 90 Tage lang archiviert, sodass er später angesehen werden kann.
- None.
- None.
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place in New York City on Wednesday, September 11, 2024, at 8:30 a.m. EDT.
A live webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Presentations" and archived for 90 days.
About Viracta Therapeutics, Inc.
Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a potentially registrational, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV+ nasopharyngeal carcinoma (NPC) and other advanced EBV+ solid tumors. Viracta is also pursuing the application of its “Kick and Kill” approach in other virus-related cancers.
For additional information, please visit www.viracta.com.
Investor Relations Contact:
Michael Faerm
Chief Financial Officer
Viracta Therapeutics, Inc.
ir@viracta.com
SOURCE Viracta Therapeutics, Inc.
FAQ
When and where will Viracta Therapeutics (VIRX) present at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Viracta Therapeutics (VIRX) at the investment conference?
How can investors access Viracta Therapeutics' (VIRX) presentation at the conference?
How long will Viracta Therapeutics' (VIRX) presentation be available for viewing after the conference?
What is the main focus of Viracta Therapeutics (VIRX) as a company?
